奥希替尼治疗表皮生长因子受体 T790M 阳性肺腺癌患者颅内快速应答。
Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung.
机构信息
Department of Medical Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
出版信息
Oncol Res Treat. 2016;39(7-8):461-3. doi: 10.1159/000446759. Epub 2016 Jun 15.
BACKGROUND
Osimertinib (AZD9291, Tagrisso) is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).
CASE REPORT
Our report demonstrates that osimertinib is able to inhibit the growth of a radiotherapy- and surgery-refractory EGFR T790M-positive brain metastasis in a patient with lung adenocarcinoma.
CONCLUSION
These data show that re-biopsy in EGFR-mutated non-small cell lung cancer patients with acquired TKI resistance should be performed.
背景
奥希替尼（AZD9291，泰瑞沙）是一种强效、不可逆的第三代表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）。
病例报告
本报告表明，奥希替尼能够抑制肺腺癌患者放疗和手术耐药的 EGFR T790M 阳性脑转移的生长。
结论
这些数据表明，对于获得性 TKI 耐药的 EGFR 突变型非小细胞肺癌患者，应进行再次活检。
Zotero 插件